Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver

Cancer Research

Volumn 66, Issue 22, 2006, Pages 11005-11012

  Subleski, Jeff J ^a   Hall, Veronica L ^a   Back, Timothy C ^b   Ortaldo, John R ^a   Wiltrout, Robert H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG VEHICLE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; LIVER CANCER; LIVER CELL; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-18; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, SCID; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 33845332083     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0811     Document Type: Article

References (45)

1. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005;40:225-35.
2. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003;3:666-75.
3. Li Z, Diehl AM. Innate immunity in the liver. Curr Opin Gastroenterol 2003;19:565-71.
4. Wick MJ, Leithauser F, Reimann J. The hepatic immune system. Crit Rev Immunol 2002;22:47-103.
5. Biron CA, Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol 2001;13:458-64.
6. Smyth MJ, Crowe NY, Hayakawa Y, et al. NKT cells: conductors of tumor immunity? Curr Opin Immunol 2002;14:165-71.
7. Smyth MJ, Wallace ME, Nutt SL, et al. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med 2005;201:1973-85.
8. Terabe M, Matsui S, Noben-Trauth N, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000;1:515-20.
9. Ortaldo JR, Winkler-Pickett RT, Bere EW, Jr., et al. In vivo hydrodynamic delivery of cDNA encoding IL-2: rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells. J Immunol 2005;175:693-9.
10. Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 1995;378:88-91.
11. Zeh HJ, III, Hurd S, Storkus WJ, Lotze MT. Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J Immunother 1993;14:155-61.
12. Dinarello CA, Fantuzzi G. Interleukin-18 and host defense against infection. J Infect Dis 2003;187 Suppl 2:S370-84.
13. Ahn HJ, Maryo S, Tomura M, et al. A mechanism underlying synergy between IL-12 and IFN-γ-inducing factor in enhanced production of IFN-γ. J Immunol 1997;159:2125-31.
14. Lauwerys BR, Renauld JC, Houssiau FA. Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine 1999;11:822-30.
15. Ajiki T, Murakami T, Kobayashi Y, et al. Long-lasting gene expression by particle-mediated intramuscular transfection modified with bupivacaine: combinatorial gene therapy with IL-12 and IL-18 cDNA against rat sarcoma at a distant site. Cancer Gene Ther 2003;10:318-29.
16. Baxevanis CN, Gritzapis AD, Papamichail M. In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18. J Immunol 2003;171:2953-9.
17. Coughlin CM, Salhany KE, Wysocka M, et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 1998;101:1441-52.
18. Oshikawa K, Shi F, Rakhmilevich AL, et al. Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1β converting enzyme cDNA. Proc Natl Acad Sci U S A 1999;96:13351-6.
19. Robinson D, Shibuya K, Mui A, et al. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-[γ] production and activates IRAK and MF[κ]B. Immunity 1997;7:571-81.
20. Osaki T, Peron JM, Cai Q, et al. IFN-γ-inducing factor/IL-18 administration mediates IFN-γ- and IL-12-independent antitumor effects. J Immunol 1998;160:1742-9.
21. Carson WE, Dierksheide JE, Jabbour S, et al. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-γ production and STAT-mediated signal transduction. Blood 2000;96:1465-73.
22. Ortaldo JR, Young HA, Winkler-Pickett RT, et al. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J Immunol 2004;172:943-53.
23. Huben RP, Connelly R, Goldrosen MH, Murphy GP, Pontes JE. Immunotherapy of a murine renal cancer. J Urol 1983;129:1075-8.
24. Fogler WE, Volker K, McCormick KL, et al. NK cell infiltration into lung, liver, and subcutaneous B16 melanoma is mediated by VCAM-1/VLA-4 interaction. J Immunol 1996;156:4707-14.
25. Wiltrout RH, Mathieson BJ, Talmadge JE, et al. Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes from the liver. J Exp Med 1984;160:1431-49.
26. Fogler WE, Volker K, Watanabe M, et al. Recruitment of hepatic NK cells by IL-12 is dependent on IFN-{γ} and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas. J Immunol 1998;161:6014-21.
27. Wilson MT, Johansson C, Olivares-Villagomez D, et al. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci U S A 2003;100:10913-8.
28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8.
29. Dunn GP, Ikeda H, Bruce AT, et al. Interferon-γ and cancer immunoediting. Immunol Res 2005;32:231-46.
30. Portielje JE, Gratama JW, van Ojik HH, Stoter G, Kruit WH. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother 2003;52:133-44.
31. Eberl G, MacDonald HR. Rapid death and regeneration of NKT cells in anti-CD3epsilon- or IL-12-treated mice: a major role for bone marrow in NKT cell homeostasis. Immunity 1998;9:345-53.
32. Tannenbaum CS, Hamilton TA. Immune-inflammatory mechanisms in IFNγ-mediated anti-tumor activity. Semin Cancer Biol 2000;10:113-23.
33. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002;2:557-68.
34. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon γ-dependent tumor surveillance system in immune-competent mice. Proc Natl Acad Sci U S A 1998;95:7556-61.
35. Street SE, Cretney E, Smyth MJ. Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis. Blood 2001;97:192-7.
36. Wigginton JM, Lee JK, Wiltrout TA, et al. Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-γ and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. J Immunol 2002;169:4467-74.
37. Son YI, Dallal RM, Lotze MT. Combined treatment with interleukin-18 and low-dose interleukin-2 induced regression of a murine sarcoma and memory response. J Immunother 2003;26:234-40.
38. Wigginton JM, Gruys E, Geiselhart L, et al. IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 2001;108:51-62.
39. Portielje JE, Lamers CH, Kruit WH, et al. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-γ, tumor necrosis factor-α, IL-6, and IL-8 responses. Clin Cancer Res 2003;9:76-83.
40. Gollob JA, Mier JW, Veenstra K, et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response. Clin Cancer Res 2000;6:1678-92.
41. Tahir SM, Cheng O, Shaulov A, et al. Loss of IFN-γ production by invariant NK T cells in advanced cancer. J Immunol 2001;167:4046-50.
42. Tartour E, Gey A, Sastre-Garau X et al. Prognostic value of intratunioral interferon γ messenger RNA expression in invasive cervical carcinomas. J Natl Cancer Inst 1998;90:287-94.
43. Wallace ME, Smyth MJ. The role of natural killer cells in tumor control-effectors and regulators of adaptive immunity. Springer Semin Immunopathol 2005;27:49-64.
44. Hammond KJ, Kronenberg M. Natural killer T cells: natural or unnatural regulators of autoimmunity? Curr Opin Immunol 2003;15:683-9.
45. Ohnishi Y, Tsutsumi A, Goto D, et al. TCR Vα14 natural killer T cells function as effector T cells in mice with collagen-induced arthritis. Clin Exp Immunol 2005;141:47-53.